1.05

0.00% 0.00

Tiziana Life Sciences Ltd (TLSA)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.05

Offen:

$1.08

24-Stunden-Volumen:

553.40K

Relative Volume:

0.84

Marktkapitalisierung:

$133.62M

Einnahmen:

Nettoeinkommen (Verlust:

$-18.43M

KGV:

-6.7394

EPS:

-0.1558

Netto-Cashflow:

$-12.87M

1W Leistung:

-11.76%

1M Leistung:

+36.35%

6M Leistung:

-21.64%

1J Leistung:

-48.02%

1-Tages-Spanne:

$1.03

$1.10

1-Wochen-Bereich:

$1.02

$1.20

52-Wochen-Spanne:

$0.7615

$2.15

Tiziana Life Sciences Ltd Stock (TLSA) Company Profile

Firmenname

Tiziana Life Sciences Ltd

Sektor

Healthcare (1052)

Branche

Biotechnology (594)

Telefon

Adresse

Mitarbeiter

Twitter

@tizianals

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

TLSA's Discussions on Twitter

Compare TLSA vs VRTX, MRNA, REGN, ARGX, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TLSA Tiziana Life Sciences Ltd	1.05	133.62M	0	-18.43M	-12.87M	-0.1558
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-09-03	Eingeleitet	BTIG Research	Buy
2020-12-22	Eingeleitet	B. Riley Securities	Buy
2018-12-17	Eingeleitet	Laidlaw	Buy

Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten

Sep 30, 2026

A rare disorder’s median survival is 6–9 years. Tiziana seeks FDA rare-disease designation for its nasal drug. - Stock Titan

Sep 30, 2026

Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com Canada

Sep 30, 2026

Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com UK

Sep 30, 2026

Sep 22, 2026

TLSA Reiterated by BTIG -- Price Target Maintained at $7.00 - GuruFocus

Sep 22, 2026

Sep 17, 2026

Tiziana Life Sciences (NASDAQ: TLSA) Enters MOU to Launch RRMS Combination Therapy Trial - Kalkine Media

Sep 17, 2026

Tiziana (TLSA) lines up MS trial for patients failing current drugs with a nasal antibody twist. - Stock Titan

Sep 17, 2026

A planned MS trial will test Tiziana’s nasal drug with existing treatment - Stock Titan

Sep 17, 2026

Sep 09, 2026

ADAG Stock Price, Quote & News - Syfe

Sep 09, 2026

Sep 08, 2026

TLSA: Tiziana Life Sciences Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 08, 2026

Sep 03, 2026

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Yahoo Finance

Sep 03, 2026

Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news

Sep 03, 2026

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Proactive financial news

Sep 03, 2026

Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks

Sep 03, 2026

Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks

Sep 03, 2026

This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Sep 03, 2026

TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - GuruFocus

Sep 03, 2026

BTIG Initiates Tiziana Life Sciences at Buy With $7 Price Target - marketscreener.com

Sep 03, 2026

BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com India

Sep 03, 2026

BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com

Sep 03, 2026

BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com UK

Sep 03, 2026

Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news

Sep 03, 2026

Aug 24, 2026

Wall Street ends on a mixed note as Dow gains despite semiconductor slump - proactiveinvestors.com.au

Aug 24, 2026

Market movers: Strategy, Bitmine, Tiziana Life Sciences... - Proactive Investors

Aug 24, 2026

Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data - Stock Titan

Aug 24, 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - kommunikasjon.ntb.no

Aug 24, 2026

Tiziana Life Sciences Ltd. - Via Ritzau

Aug 24, 2026

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 - Yahoo Finance

Aug 24, 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - The Manila Times

Aug 24, 2026

Aug 11, 2026